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ABSTRACT 21 
The highly effective DNA vaccines against diseases caused by fish rhabdoviruses in farmed fish 22 
consist of a DNA plasmid vector encoding the viral glycoprotein under the control of a 23 
constitutive cytomegalovirus promoter (CMV). Among others, attempts to improve efficacy and 24 
safety of these DNA vaccines have focused on regulatory elements of plasmid vectors, which 25 
play a major role in controlling expression levels of vaccine antigens. Depending on the 26 
context, use of a fish-derived promoter with minimal activity in mammalian cells could be 27 
preferable. Another aspect related to the CMV promoter is that constitutive expression of the 28 
vaccine antigen may lead to rapid elimination of antigen expressing cells in the fish and 29 
thereby potentially reduce the long-term effects of the vaccine.  30 
In this study, we compared DNA vaccines with the interferon-inducible Mx promoter from 31 
rainbow trout and the CMV promoter, respectively. Plasmid constructs encoding the enhanced 32 
green fluorescent protein (EGFP) were used for the in vitro analysis, whereas DNA vaccines 33 
encoding the glycoprotein (G) of the viral haemorrhagic septicaemia virus (VHSV) were applied 34 
for the in vivo examination.  35 
The in vitro analysis showed that while the DNA vaccine with the CMV promoter constitutively 36 
drove the expression of EGFP in both fish and human cell lines, the DNA vaccine with the Mx 37 
promoter inducibly enhanced the expression of EGFP in the fish cell line. 38 
To address the impact on protection, a time-course model was followed as suggested by 39 
Kurath et al. (2006), where vaccinated fish were challenged with VHSV at 2, 8 and 78 weeks 40 
post-vaccination (wpv). The DNA vaccine with the CMV promoter protected at all times, while 41 
vaccination with the DNA vaccine containing the Mx promoter only protected the fish at 8 wpv. 42 
However, following induction with Poly(I:C) one week before the challenge, high protection 43 
was also evident at 2 wpv.  44 
In conclusion, the results revealed a more fish host dependent activity of the trout Mx 45 
promoter compared to the traditionally used cross species-active CMV promoter, but 46 
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improvements will be needed for its application in DNA vaccines to ensure long term 47 
protection.  48 
INTRODUCTION 49 
Viral haemorrhagic septicaemia virus (VHSV), a member of the Rhabdoviridae family [1], 50 
causes a severe disease (VHS) in wild and farmed fish worldwide [2]. Several vaccination 51 
strategies have been tested against VHS, including inactivated virus vaccines, live-attenuated 52 
virus vaccines, and recombinant vaccines. However, due to low efficacy, high cost per dose, or 53 
safety limitations, there is currently no commercially available vaccine against VHS [3-7]. In 54 
1998, the evaluation of a DNA vaccine as an alternative immunization strategy against VHS 55 
revealed the establishment of highly protective immunity [8]. Since then, several studies have 56 
examined the protection induced by DNA vaccination against VHS and the related disease IHN 57 
(infectious haematopoietic necrosis) under different experimental conditions, with promising 58 
results [9, 10]. The DNA vaccines typically include an eukaryotic expression plasmid vector 59 
encoding the viral surface glycoprotein (G), under the control of the human cytomegalovirus 60 
promoter (CMV). The immunological protection follows a sequential three-phase scenario [10], 61 
which involves: 62 
(i) The early antiviral response (EAVR), which comprise cross-reactive protection 63 
associated with innate antiviral immune mechanisms. This protective phase starts 64 
shortly (within days) after the intramuscular injection of the DNA vaccine but only 65 
lasts for a few weeks. It is characterized by up-regulating the expression of 66 
interferon type I (IFN I), and consequently also increased transcription of multiple 67 
interferon-stimulated genes (ISG) [11-15].  68 
(ii) The specific antiviral response (SAVR), which starts a few weeks after vaccination, 69 
when cross-protection against heterologous virus fades away and adaptive 70 
immunity characterized by neutralizing antibodies and cytotoxic T lymphocytes 71 
(CTL) appear [16-18].  72 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
(iii) The long-term antiviral response (LAVR), which follows the SAVR, is characterized 73 
by slightly lower protection than in SAVR and minimal levels or absence of 74 
neutralizing antibodies in fish which have not been exposed to virus. This phase like 75 
the SAVR, is thought to be associated with specific adaptive immune mechanisms, 76 
although this remains to be demonstrated [10, 18].  77 
Considering that the persistence of a plasmid in fish tissue could last up to 535 days after 78 
intramuscular injection [19, 20], DNA vaccine residues might be present at the time of 79 
slaughter. Although there are no indications of consumer safety issues related to the CMV 80 
promoter [21, 22], this aspect has earlier driven the search for alternative, fish-derived, 81 
promoters for DNA vaccines to be used in aquacultured fish [23, 24], and was also discussed 82 
more recently by Alonso and Leong [25] 83 
Example of fish-derived promoters tested in DNA vaccines are the Interferon regulatory factor 84 
1A (IRF1A) promoter,  the Mx1 promoter and the carp β-actin (AE6) promoter [23, 24, 26-28]. 85 
Some of the examined DNA vaccines with alternative promoters have shown potential in terms 86 
of inducing protective immunity [23, 24]. However, the reports published so far have not taken 87 
the time-course scenario of the protective mechanisms into account considering both 88 
specificity and duration of protection. The time-course study is important from a practical point 89 
of view, where the ability of the vaccine to induce a fast, efficient, and long-lasting protection, 90 
is essential.  91 
Another aspect of the strong constitutive antigen expression mediated by the CMV promoter in 92 
vaccinated animals relates to the rather efficient elimination of transfected cells by infiltrating 93 
leucocytes [29]. Reduced persistence of antigen may imply shorter duration of immunity, and 94 
it may be speculated that more long lasting and possibly controlled onset of immunity could be 95 
obtained by a using an inducible promoter.  96 
This work aimed to analyze the capacity of a VHSV glycoprotein DNA vaccine with an IFN-97 
inducible trout-derived Mx 1 promoter to induce EAVR, SAVR, and LAVR in rainbow trout 98 
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fingerlings. To address thehost range aspect of promoter activity, we also compared 99 
expression of the recombinant protein in transfected cell lines derived from fish and humans.  100 
 101 
MATERIALS AND METHODS 102 
 103 
Cell lines. EPC cells (epithelioma papulosum cyprinid) [30], BF2 cells (bluegill fry fibroblast) 104 
[31], HeLa cells (ATCC®CCL-2), and FHs74 (ATCC®CCL241) [32] were used in this work. BF2 105 
and HeLa cells were maintained in minimum essential media (MEM), EPC cells in RPMI 1640 106 
medium and FHs74 cells in Hybri-Care Medium (ATCC® 46-X™) supplemented with 30 ng/ml 107 
epidermal growth factor (EGF). All media were supplemented with 10% fetal bovine serum 108 
(FBS), 100 U/ml of Penicillin and 100 µg/ml of Streptomycin. EPC and BF2 were maintained at 109 
15°C, while HeLa and FHs74 were maintained at 37°C. 110 
Virus. A low passaged VHSV isolate (DK3592b) was propagated by inoculating freshly 111 
passaged BF2 cells with a low MOI (multiplicity of infection). The infected cell cultures were 112 
maintained at 15°C. When a complete cytopathic effect was observed, the medium was 113 
centrifuged at 5,000 x g for 15 min at 4°C. The supernatant was collected and the titer of the 114 
virus was determined using the method of 50% tissue culture infective doses (TCID50) per ml 115 
in BF2 cells [33]. Virus batches were stored in aliquots at -80oC. 116 
Plasmid constructs. An expression vector with Mx promoter (pcDNA3-Mx) was constructed 117 
by replacing the CMV promoter of pcDNA3 (Invitrogen), with the Mx1 promoter from pGL3-118 
Basic-PrMx1 [27]. The pcDNA3 vector was named pcDNA3-CMV in this work. Further details in 119 
Figure 1. To evaluate the specificity of the immune protection induced by the VHS- DNA 120 
vaccine in the challenges performed at 2 and 8 wpv, a group of trout was vaccinated with the 121 
plasmid pcDNA3.1-CMV-ihnG, encoding the glycoprotein of the IHNV (isolate US-WRAG) [34]. 122 
This IHNV-DNA vaccine should be able to induce EAVR (innate immune mechanisms) but not 123 
SAVR (Adaptive immune mechanisms) against VHS in vaccinated rainbow trout 124 
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 Escherichia coli transformed with each plasmid were propagated overnight in 4 L of LB broth 125 
containing ampicillin (100 µg/ml), at 37oC. An endofree plasmid purification kit (Gigaprep kit 126 
Qiagen) was used for the further purification of the DNA constructs. The DNA constructs for the 127 
vaccination trials and the in vitro evaluations are listed in Table 1. 128 
 129 
 130 
Figure 1. Schematic outline of the construction of the DNA vaccines with the IFN-131 
inducible Mx promoter. The Mx1 promoter was excised from pGL3-Basic-PrMx1 as a 600 bp 132 
MluI-BglII fragment and inserted into pcDNA3-CMV digested with MluI and BamHI. The IFN-133 
regulated expression vector encoding the VHSV glycoprotein (pcDNA3-Mx-vhsG) was obtained 134 
by excising the VHSV glycoprotein gene (vhsG) from pcDNA3-vhsG [35] as a 1576 bp EcoRI-135 
EcoRI fragment and ligating it into pcDNA3-Mx digested with EcoRI. The plasmid pcDNA3-vhsG 136 
was denominated pcDNA3-CMV-vhsG in this work. The glycoprotein gene was derived from 137 
VHSV isolate DK3592b. For the in vitro evaluation, the glycoprotein coding sequence from both 138 
pcDNA3-CMV-vhsG and pcDNA3-Mx-vhsG were excised with EcoRI and NotI and replaced with 139 
the EGFP gene, which was excised from pEGFP-N1 (Clontech) using the same endonucleases. 140 
The empty vectors with CMV and Mx promoters (pcDNA3-CMV and pcDNA3-Mx) were used as 141 
negative controls. 142 
 143 
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Table 1: Plasmid constructs 144 
Plasmids Promoter Encoded protein 
pcDNA3-CMV CMV - 
pcDNA3-CMV-vhsG CMV VHSV glycoprotein 
pcDNA3-CMV-EGFP CMV EGFP 
pcDNA3-Mx IFN-inducible Mx promoter - 
pcDNA3-Mx-vhsG IFN-inducible Mx promoter VHSV glycoprotein 
pcDNA3-Mx-EGFP IFN-inducible Mx promoter EGFP 
pcDNA3.1-CMV-ihnG  CMV IHNV glycoprotein 
 145 
Evaluation of promoter activity in cell culture 146 
EPC, FHs74 and HeLa cells were seeded in 24-well plates (2x105 cells/well) one day before 147 
transfection. The transfection was performed with the plasmids: pcDNA3-CMV, pcDNA3-CMV-148 
EGFP, pcDNA3-Mx, and pcDNA3-Mx-EGFP. Briefly, 0.75 µg of either construct was mixed with 149 
2 µg of PEI (Polyethylenimine) in 300 µl of medium without serum, and incubated for 20 min 150 
at room temperature. The medium from each well was removed and replaced by the 151 
transfection mix. At 6 h post-transfection for the EPC cells and 4 h for the Hela and the FHs74 152 
cells, the cell culture medium was replaced by fresh medium with or without Poly(I:C) 153 
(P0913,Sigma) (a potent inducer of IFN) to a final concentration of 10 µg/ml.  154 
The EPC cell culture was evaluated at 7 days post-transfection, while the HeLa and FHs74 cell 155 
cultures were evaluated by fluorescence microscopy at 2 days after transfection. The images 156 
were obtained with a Leica TCS SP2 laser scanning confocal microscope (Leica, Germany), and 157 
processed by the Leica confocal software. 158 
 159 
Evaluation of EAVR and SAVR   160 
Outbreed, all female rainbow trout with average weight of 3.5 g (EAVR) or 1.8 g (SAVR) were 161 
used for the vaccination trials. The fish were anesthetized in 0.01% benzocaine (Sigma) and 162 
then injected intramuscularly (I.M.) with 1 µg of either of the plasmids encoding VHSV G or 163 
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with the plasmids with no transgene (Table 1) in 25 µl of saline solution (0.9% NaCl). At one 164 
week post-vaccination, the fish vaccinated with either pcDNA3-Mx or with pcDNA3-Mx-vhsG 165 
were split into two subgroups. One subgroup was injected intraperitoneally (I.P.) with 1 µg of 166 
Poly(I:C)/g fish in 50 µl of saline solution, and the second subgroup was injected with 50 µl of 167 
saline solution (Fig. 2). After vaccination, the fish were maintained in 120 L aerated aquaria 168 
supplied with recirculated water at 8-10°C in a pathogen-free laboratory facility until 169 
challenge. 170 
For evaluation of EAVR and SAVR, challenge with the virulent VHSV isolate DK3592b was 171 
performed at 2 and 8 weeks post-vaccination, respectively (Fig. 2). The fish were kept in 172 
aerated running fresh water in 8 L aquaria with 2-3 replicates of 25-33 fish per treatment. The 173 
challenge was carried out by immersion in static freshwater with an infectious dose of 2-3x105 174 
TCID50 /ml of water. After 2 h, the water flow was re-established. During the following 3 175 
weeks, temperature and mortality/survival were registered on a daily basis. Fish with evident 176 
clinical signs were euthanized with an overdose of benzocaine. Representative samples of 177 
dead/terminated fish were examined virologically from all aquaria as described earlier [16, 178 
36].  179 
 180 
Evaluation of the LAVR  181 
Outbreed all female rainbow trout (2 - 5g) were divided into 5 groups, 4 of them injected I.M. 182 
with 1 µg of either of the plasmids applied in the first vaccination trial in 25 µl of saline 183 
solution, and one group injected with 25 µl of a saline solution. Each group contained 120 fish, 184 
which were maintained in 120 L aerated aquaria supplied with recirculated water at 8-10°C in 185 
a pathogen-free laboratory facility. At 68 weeks post-vaccination, the groups of fish previously 186 
injected with saline solution, pcDNA3-Mx, or pcDNA3-Mx-vhsG were split into 2 subgroups. The 187 
fish of one subgroup were injected I.P. with 100 µl of saline solution, while the fish of the 188 
second subgroup were injected I.P. with 100 µg of Poly(I:C) in 100 µl of saline solution (Fig. 189 
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2). The fish injected with pcDNA3-CMV, and pcDNA3-CMV-vhsG were injected only with the 190 
saline solution. At this time, the weight of the fish was 40-70 g. 191 
The challenge was performed at 78 weeks post-vaccination (10 weeks post-induction with 192 
Poly(I:C). The virus challenge was carried out as described above, with a virus titer of 3x104 193 
TCID50 /ml in 3 replicate 8 L aquaria of 20 fish per treatment. 194 
Temperature and mortality/survival were registered daily for 30 days. The fish with evident 195 
clinical signs were euthanized with an overdose of benzocaine. The relative percentage survival 196 
(RPS) was calculated: RPS=[1-(% mortality of immunized fish / % mortality of control 197 
fish)]x100. 198 
 199 
Figure 2. Timelines of vaccination/challenge trials. (A) EAVR, (B) SAVR, (C) LAVR.  200 
 201 
 202 
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Animal experiments. All animal experiments were performed according to European and 203 
Danish rules for the use of experimental animals. The experiments were approved by Danish 204 
Animal Experiments Inspectorate under license No. 2014-15-0201-00379.  205 
Statistical analysis 206 
Statistically significant differences of the cumulative mortalities were performed using RStudio 207 
v. 1.0.143 [37, 38]  by one-way analysis of variance (ANOVA) followed by Tukey´s post hoc 208 
test [39], with p< 0.05 considered statistically significant. 209 
 210 
RESULTS 211 
Evaluation of promoter activity in cell culture 212 
EPC, HeLa, and FHs74 cell lines transfected with pcDNA3-CMV-EGFP expressed EGFP  whether 213 
treated with Poly(I:C) or not. The intensity of fluorescence and the number of EGFP-positive 214 
EPC cells was higher than that of EPC cell cultures transfected with pcDNA3-Mx-EGFP (Fig. 3A,  215 
B, E, F, I, J). 216 
EPC cell cultures transfected with pcDNA3-Mx-EGFP but not treated with Poly(I:C) showed only 217 
a few cells expressing EGFP with low intensity of fluorescence (Fig. 3C). When these cell 218 
cultures were treated with Poly(I:C) more positive cells with higher intensity of fluorescence 219 
were seen (Fig. 3D), indicating induction of the Mx promoter. The HeLa and FHs74 cell cultures 220 
transfected with pcDNA3-Mx-EGFP showed no expression of EGFP even when stimulated with 221 
Poly(I:C) (Fig. 3 G, H, K, L). 222 
No fluorescence signal was observed in all cell lines transfected with pcDNA3-CMV and 223 
pcDNA3-EGFP (data not shown). 224 
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 225 
Figure 3. Expression of EGFP in transfected cell cultures. A: EPC cells transfected with 226 
pcDNA3-CMV-EGFP untreated with Poly(I:C). B: EPC cells transfected with pcDNA3-CMV-EGFP 227 
treated with Poly(I:C). C: EPC cells transfected with pcDNA3-Mx-EGFP untreated with 228 
Poly(I:C). D: EPC cells transfected with pcDNA3-Mx-EGFP treated with Poly(I:C). E: HeLa cells 229 
transfected with pcDNA3-CMV-EGFP untreated with Poly(I:C). F: HeLa cells transfected with 230 
pcDNA3-CMV-EGFP treated with Poly(I:C). G: HeLa cells transfected with pcDNA3-Mx-EGFP 231 
untreated with Poly(I:C). H: HeLa cells transfected with pcDNA3-Mx-EGFP treated with 232 
Poly(I:C). I: FHs74 cells transfected with pcDNA3-CMV-EGFP untreated with Poly(I:C). J: 233 
FHs74 cells transfected with pcDNA3-CMV-EGFP treated with Poly(I:C). K: FHs74 cells 234 
transfected with pcDNA3-Mx-EGFP untreated with Poly(I:C). L: FHs74 cells transfected with 235 
pcDNA3-Mx-EGFP treated with Poly(I:C). The images were obtained by Leica TCS SP2 laser 236 
scanning confocal microscope. Images were processed by the Leica confocal software. 237 
 238 
Evaluation of the EAVR and the SAVR   239 
The challenge performed at 2 wpv showed that the DNA vaccine with the IFN-inducible Mx 240 
promoter (pcDNA3-Mx-vhsG) was able to induce protection consistently (RPS=67.8) in all 241 
replicates when the fish were treated with Poly(I:C). Without Poly(I:C), protection was 242 
marginal, and although the fish vaccinated with the control plasmid (pcDNA3-Mx) treated with 243 
Poly(I:C) also showed slightly lower mortality than fish untreated with Poly(I:C), the combine 244 
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protective effect was still lower than that provided by pcDNA3-Mx-vhsG + Poly(I:C) (Table 2, 245 
Fig. 4A). When immunization with pcDNA3-Mx-vhsG was evaluated in a challenge at 8 wpv, 246 
protection was independent of Poly(I:C) stimulation (Table 3, Fig. 4B). The reference DNA 247 
vaccine with CMV promoter (pcDNA3-CMV-vhsG) induced high protection at both 2 and 8 wpv, 248 
while the CMV-plasmids without the G gene did not induce any protection against VHS (Fig. 4). 249 
The vaccine encoding the IHNV G protein only was able to induce protection against VHS 250 
challenge at 2 wpv, indication that cross-protective mechanisms of innate immunity were 251 
involved at this time point, while adaptive/specific mechanisms increasingly provided 252 
protection at 8wpv where only the homologous vaccine encoding the VHSV G protein protected 253 
the fish, as reported earlier [34].  254 
Table 2: Protection by the DNA vaccines against VHSV challenge at 2 weeks post-vaccination.  255 
Groups 
Induction 
1wpv 
Cumulative 
Mortality(%) 
Mortality in replicate 
aquaria** (%) 
RPS* 
 
pcDNA3-CMV Saline 97.3 100; 96;96 0.0 
pcDNA3-CMV-vhsG Saline 0.0 0.0; 0.0; 0.0 100 
pcDNA3-Mx Poly(I:C) 76.3 80; 68; 81 21.5 
pcDNA3-Mx Saline 96 96; 96 1.3 
pcDNA3-Mx-vhsG Poly(I:C) 28.6 28; 38; 20 67.8 
pcDNA3-Mx-vhsG Saline 66.3 69; 58; 72 31.8 
pcDNA3.1-CMV-ihnG Saline 0.0 0.0; 0.0; 0.0 100 
*RPS: Relative percentage survival. 256 
** Replicate aquaria with 24-27 fish in each. 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
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Table 3: Protection induced by the DNA vaccines against VHSV challenge at 8 weeks post-265 
vaccination 266 
Groups 
Induction 
1wpv 
Cumulative 
Mortality(%) 
Mortality in replicate 
aquaria** (%) 
 RPS* 
 
pcDNA3-CMV Saline 98.9 100; 100; 96.8 0.0 
pcDNA3-CMV-vhsG Saline 4.2 3.3; 0.0; 9.4 95.7 
pcDNA3-Mx Poly(I:C) 100 100; 100; 100 -1.1 
pcDNA3-Mx Saline 100 100; 100; 100 -1.1 
pcDNA3-Mx-vhsG Poly(I:C) 23.9 25.8; 23.3; 22.6 75.8 
pcDNA3-Mx-vhsG Saline 20.4 23.5; 19.3; 18.2 79.4 
pcDNA3.1-CMV-ihnG Saline 92.4 89.7; 93.5; 93.8 6.7 
*RPS: Relative percentage survival. 267 
**Replicate aquaria with 28-34 fish in each. 268 
 269 
 270 
 271 
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 272 
 273 
Figure 4. Development of mortality in groups of DNA vaccinated rainbow trout following 274 
immersion challenge with VHSV at 2 and 8 weeks post-vaccination. A: challenge performed at 275 
2 weeks post-vaccination. B: challenge performed at 8 weeks post-vaccination.  The legend 276 
indicates the fish groups given I.M. injections of DNA plasmid followed by I.P. injections of 277 
saline or Poly(I:C) one week later.  278 
 279 
Evaluation of the LAVR  280 
The challenge performed at 78 wpv showed that immunization with the reference DNA vaccine 281 
pcDNA3-CMV-vhsG induced long-term protection against VHS, while the DNA vaccine with the 282 
Mx promoter did not elicit any protection at this time, independent of exposure to Poly(I:C) 283 
(Table 4). On average, the fish immunized with pcDNA3-Mx-vhsG showed a lower cumulative 284 
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mortality than the group given plasmid without insert, but this difference was not significant. A 285 
relatively high variability in mortality was evident between replicate aquaria in some of the 286 
groups, possibly reflecting that immersion challenge of relatively larger fish (50-70g) is more 287 
sensitive to small tank variations compared to challenge trials with small (3-10g) fish. (Fig. 5). 288 
Table 4. Protection induced by the DNA vaccines against VHSV challenge at 78 weeks post-289 
vaccination 290 
Groups 
Inductio
n 68 wpv 
Cumulative 
Mortality (%) 
Mortality in replicate 
aquaria** (%) 
RPS* 
 
pcDNA3-CMV Saline 90.41 88.9; 88.2; 94.1 0.0 
pcDNA3-CMV-vhsG Saline 17.6 11.8; 35.3; 5.9 80.48 
pcDNA3-Mx*** Poly(I:C) 79.4  50.0; 100.0; 88.2 12.2 
pcDNA3-Mx Saline 86.3 70.6; 94.1; 94.1 4.6 
pcDNA3-Mx-vhsG*** Poly(I:C) 76.6 94.4; 88.2; 47.0 15.3 
pcDNA3-Mx-vhsG*** Saline 65.2 72.2; 47.0; 76.5 27.8 
*RPS: Relative percentage survival 291 
**Replicate aquaria with 17-18 fish in each. 292 
*** High variability among replicates 293 
 294 
Figure 5. Development of mortality in groups of DNA vaccinated rainbow trout following 295 
immersion challenge with VHSV at 78 weeks post-vaccination. The legend indicates the fish 296 
groups given I.M. injections of DNA plasmid followed by I.P. injections of saline or Poly(I:C) 68 297 
weeks later. 298 
 299 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
DISCUSSION 300 
In this study, we performed a functional characterization of a DNA vaccine with an IFN-301 
inducible Mx promoter derived from rainbow trout. This involved an analysis of the expression 302 
activity in both human and fish cell lines, and an evaluation of the protection during the three 303 
antiviral immune response phases. These phases, EAVR, SAVR, and LAVR were classified 304 
according to the timing and nature of the presumed protective mechanisms [10, 18]. 305 
The in vitro results showed that the DNA vaccine plasmid with the IFN-inducible Mx promoter 306 
from rainbow trout was able to drive the expression of EGFP in transfected cells of the EPC fish 307 
cell line, but not in the tested human cell lines, while the vaccine construct with the CMV 308 
promoter drove strong expression of EGFP in both fish and human cell lines. The expression 309 
activity of the Mx promoter in the EPC cells was partly IFN-dependent as it was increased by 310 
Poly(I:C) treatment. Similar results were obtained using DNA vaccines encoding for the VHSV 311 
glycoprotein (data not shown). The transcription factors involved in the intracellular induction 312 
pathway for IFN-stimulated genes (ISGs), as well as Interferon-stimulated response elements 313 
(ISREs),  are well conserved between teleosts and higher vertebrates [27, 40]. Therefore, it 314 
seems unlikely that lack of functionality of the trout Mx promoter in the HeLa and FHs74 cell 315 
lines was due to a lack of cross-reactivity at the level of the transcription factors or ISREs. 316 
However, considering that the  IFN promoter sequences  in human and trout are different [27, 317 
41-43], and since EPC cells were grown at 15°C, while HeLa and FHs74 cells were grown at 318 
37°C, one possibility could be that temperature-dependent conformation of the Mx promoter 319 
region interfered with activation of transcription in human cell lines... Although there are 320 
currently no concerns about consumers eating DNA-vaccinated fish each vaccine construct will 321 
be evaluated on an individual basis [44] and the lack of activity of the trout Mx promoter in 322 
human cells could make it attractive for some fish DNA vaccines.  323 
Since the initial reports of the high efficacy of the CMV promoter-based DNA vaccines against 324 
rhabdoviral fish diseases [35, 45], considerable efforts have been made to identify alternative 325 
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promoters that may be more appropriate for driving expression in aquacultured fish [23, 24, 326 
28]. However, these studies have either been based on quantitative expression analysis in 327 
vitro in transfected cell cultures and/ or a single challenge test in vivo, typically 4-6 weeks 328 
post-vaccination. Our results demonstrate that to evaluate the applied potential of a DNA 329 
vaccine, it is necessary to examine protection against disease in vivo in all three phases of the 330 
immune response to the vaccine.  331 
Back in 2003, Alonso et al. reported rather low protection (RPS=16) against IHN in 0.4 g 332 
rainbow trout fry following DNA vaccination with a trout Mx promoter IHNV-G gene construct, 333 
resembling that used for VHSV glycoprotein in the current study. However, since the challenge 334 
was performed at one-month post-vaccination with fish kept at 13°C, the authors could not 335 
exclude that the observed protection with the CMV promoter reference construct might be due 336 
to innate mechanisms, i.e. the EARV (24). Indeed, in the present study we observed low 337 
protection at the presumed time of EARV (RPS=31.8), in pcDNA3-Mx-vhsG vaccinated fish. 338 
Injection of Poly(I:C) one week before challenge highly improved the protection obtained 339 
(RPS=67.8), likely due to Poly(I:C) induced IFN upregulating the expression of VHSV G as well 340 
as directly contributing to the protection seen [24, 26, 28]. The high protection (RPS=75.8) 341 
against VHSV challenge at 8 wpv in fish given the pcDNA3-Mx-vhsG, even without Poly(I:C) 342 
stimulation, suggested that the baseline activity of the Mx promoter (as visualized in the in 343 
vitro evaluation) was sufficient to trigger a protective SAVR. However, since no heterologous 344 
pcDNA3-Mx-ihnG was included, we cannot fully exclude that EARV mechanisms might have 345 
contributed to the protection. [13, 14]. In mammals, IFN and related innate antiviral immune 346 
mechanisms are important not only for protection at the early stage of viral infection but also 347 
for paving the way for an effective adaptive response [46, 47]. Assuming that this also occurs 348 
in salmonid fish, as indicated by an adjuvant effect of type I IFNs [46, 48], the combination of 349 
poor early protection with high (assumed) - specific protection in fish vaccinated with pcDNA3-350 
Mx-vhsG suggests that there may be qualitative and/or quantitative differences between the 351 
IFN response elements activating the EAVR mechanisms involved in protection and the ones 352 
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promoting an efficient induction of SAVR /LAVR. Also, there may be distinct requirements to 353 
reach a protective LAVR on top of, or separate to, those needed for a protective SARV. Further 354 
experiments including examination of the specificity of the protection induced by the pcDNA3-355 
Mx-vhsG vaccine at 8 wpv along with immune gene expression analysis are needed to resolve 356 
this aspect. Interestingly, Chang et. al. (2015) showed that while  IFNa, IFNb, or IFNc plasmid 357 
constructs all had an adjuvant effect, promoting generation of a protective adaptive immune 358 
response to a co-injected DNA vaccine against Infectious salmon anaemia (ISA) in Atlantic 359 
salmon, only IFNc was able to provide protection against this disease without needing the 360 
expression of the viral antigen [46].  361 
The protective effect at 78 wpv reported here for the pcDNA3-CMV-vhsG vaccinated fish along 362 
with earlier observations by Kurath et al demonstrating immunity to IHN 2 years post-363 
vaccination [18] suggests that the salmonid rhabdovirus G-gene DNA vaccines with CMV-364 
promoter driven expression induce long lasting immunity covering the typical 2-3-year lifespan 365 
for cultured rainbow trout. However, such long term studies have not been conducted for other 366 
fish DNA vaccines, and a similar duration of immunity may not be expected. For the Mx 367 
promoter DNA vaccine construct tested here, our initial hypothesis was that without Poly(I:C) 368 
or IFN stimulation, no or low levels of vaccine antigen expression would occur in fish 369 
vaccinated with pcDNA3-Mx-vhsG. In that case, elimination of cells harboring the plasmid by 370 
the local inflammatory response, described in fish vaccinated with pcDNA3-CMV-vhsG [29], 371 
would be less likely to occur or at least delayed. This could extend the lifetime of the vaccine in 372 
the fish and possibly allow post-vaccination management of the fish immune status by internal 373 
or external IFN stimulation. However, even with Poly(I:C) stimulation 10 weeks earlier, 374 
vaccination with pcDNA3-Mx-vhsG failed to protect the fish against VHS. It remains to be 375 
determined whether this was due to elimination of transfected cells before the Poly(I:C) 376 
stimulation, or because the baseline expression level of the antigen by the Mx promoter was 377 
insufficient to induce long-term memory. In applied terms, future research should address 378 
whether the fish specificity of the trout Mx promoter could be combined with the high 379 
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expression capacity of other promoters by designing hybrid promoters as previously attempted 380 
by Martinez-Lopez et al. (2013) [28]. Also, it must be analyzed whether the trout Mx promoter 381 
might increase the chance of integration by homologous recombination in vaccinated rainbow 382 
trout. Since the trout Mx promoter also worked in cyprinid cells, this issue could be addressed 383 
by the use of heterologous fish promoters when designing DNA vaccines for a particular fish 384 
species.  385 
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- DNA vaccine with Poly(I:C) inducible Mx promoter. 
- Selective expression in fish cells. 
- Immunity to VHS induced by DNA vaccine with CMV promoter last more than 17 months. 
- No direct link between early and specific protection following DNA vaccination.  
